Skip to main content

Table 1 Characteristics of studies included in the final meta-analysis of Ki-67 expression and prognosis of NSCLC

From: Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies

First-Author and Year

Country

Total Patients, H/L

Mean age

Gender (M/F)

History

TNM Stage

Antibody and dilution

Cut-off (%)

Followup (median Month)

Survival Analysis, year

HR estimated

OS/DFS HR (95%CI)

Study Quality

Ahn 2014

Korea

109,20/89

65

65/44

NSCLC

I-III

Anti-Ki67; 1:50

40

30

OS/DFS,5

S.urves

O:1.60(0.74-3.44) D:2.875(1.326-6.234)

34

Cagini 2000x

Italy

99,43/56

66

91/8

NSCLC

I-II

MIB-1; 1:100

20

41

OS, 5

Events

O:1.33(0.72-2.43)

31

D’amico 1999

USA

408,204/204

62.9

269/139

NSCLC

I

MIB-1, NA

7

60

OS,5

Events

O:1.41(0.99-2.00)

33

Demarchi 2000

Brazil

64,32/32

59.8

43/21

ADC

I-III

MIB-1; 1:400

22.2

51.9

OS,5

R

O:0.49(0.20-1.22)

31

Fontanini 1996

Italy

65,31/34

46

63/7

NSCLC

I-III

MIB-1; 1:200

30.2

45

OS,3

R

O:1.05(0.83-1.324)

34

Haga 2003

Japan

187,112/75

NA

120/67

ADC,SCC

I

MIB-1; 1:100

10

120

OS,5

Events

O:3.636(1.267-10.439)

33

Harpole 1996

USA

275,109/106

63

177/98

NSCLC

I

Anti-Ki67; NA

7

68

OS, 5

Events

O:1.53(1.00-2.37)

34

Hayashi 2001

Japan

98,36/62

62.7

56/42

ADC

I-III

MIB-1; 1:200

12.6

60

OS,5

R

O:2.0(1.1-3.8)

29

Hommura 2000

Japan

215,116/99

63.3

144/71

NSCLC

I-IV

MIB-1; 1:50

30

84

OS,3

R

O:2.53(1.35-4.72)

34

Huang 2005

Japan

173,117/56

67

116/57

NSCLC

I-III

MIB-1; 1:40

25

77

OS,5

Events

O:1.56(0.99-2.44)

32

Ishida 1997

Japan

114,57/57

64.9

59/55

ADC

I-II

MIB-1; 1:50

22.7

28.5

OS,5

S.urves

O:8.50(3.52-20.53)

32

Kaira 2008

Japan

361,186/135

67

196/125

NSCLC

I-III

MIB-1; 1:40

25

48

OS,5

R

O:0.667(0.271-1.643)

32

Liu 2012a

China

494,113/381

61

366/128

ADC,SCC

I-IV

Anti-Ki67; 1:200

50

25.9

OS,5

R

O:1.583(1.100-2.277)

32

Liu 2012b

China

174,88/79

60

133/41

ADC,SCC

I-IV

Anti-Ki67; 1:200

50

25

OS,5

R

O:1.681(0.487-5.797)

32

Maddau 2006

Italy

180,103/77

65.5,

151/29

NSCLC

I-III

MIB-1; 1:50

25

3-47

OS,3

R

O:0.79(0.55-1.15)

29

Mehdi 1998

USA

243,154/49

63.5

184/76

NSCLC

I-II

MIB-1; 1:150

25

60

OS/DFS,3

S.urves

O:1.60(1.06-2.41) D:1.58(1.06-2.41)

36

Minami 2002

Japan

47,22/25

64

28/19

ADC

I

MIB-1; NA

20

89

OS,5

R

O:1.022(0.96-1.08)

33

Navaratnam 2012a

Canada

79,37/42

69.2

47/32

NSCLC

I-II

MIB-1; 1:50

20

36

OS,3

R

O: 1.81(0.93-3.53)

30

Navaratnam 2012b

Cadana

58,20/38

62.8

23/35

NSCLC

I-II

MIB-1; 1:50

10

36

OS,3

R

O:1.31(0.68-2.52)

24

Nguyen 2000

Czech

89,34/55

60

73/16

NSCLC

I-IV

MIB-1; NA

30

36

OS,3

S.urves

O:2.15(1.21-3.78)

28

Pence 1993

USA

61,15/46

63

56/5

NSCLC

I-IV

Anti-Ki67; 1:100

PI 3.5

38

OS,5

S. urves

O:2.18(1.00-4.78)

29

Poleri 2003

Argentina

50,28/22

60.8

NA

ADC,SCC

I

MIB-1; NA

33

59

DFS,5

Events

D:4.10(1.98-8.46)

33

Puglisi 2002

Italy

81,28/53

62.5

NA

ADC,SCC

I-III

MIB-1; 1:100

34.2

115.76

OS,5

R

O: 1.29(0.71-2.31)

33

Ramnath 2001

USA

212,118/94

63.7

111/101

NSCLC

I-IV

MIB-1; 1:100

25

24.3

OS,3

S. Curve

O:1.41(0.93-2.12)

31

Shiba 2000

Japan

156,81/75

62.4

112/44

NSCLC

I-III

MIB-1; 1:100

20

49

OS,5

S. Curve

O:2.20(1.38-3.53)

34

Takahashi 2002

Japan

62,22/40

66.9

40/22

ADC,SCC

I-II

MIB-1; 1:100

25

3.9

DFS,5

R

D:1.02(0.32-3.30)

33

Warth 2014

Germany

482,230/252

63.2

NA

ADC

I-IV

MIB-1, 1:500

25

45.6

OS/DFS,5

S. Curve

O:1.86(1.29-2.69) D:1.29(1.02-1.64)

29

Woo 2009

Japan

184,79/105

67.8

92/92

NSCLC

I

MIB-1; NA

10

35.9

DFS,5

R

D:3.84(1.18-12.45)

34

Wu 2013

China

192,120/72

59

104/88

NSCLC

I-III

Anti-Ki67; 1:200

10

60

OS/DFS,5

R

O:2.829(1.26-4.525) D:2.929(2.184-4.928)

32

Yamashita 2011

Japan

44,13/31

NA

25/19

NSCLC

I

Anti-Ki67; 1:100

5

60

DFS,5

R

D:12.5(1.1-140.7)

33

Yoo 2007

Korea

219,17/209

65.8

168/51

ADC,SCC

I-III

Anti-Ki67; NA

30

38.9

OS,5

R

O:0.827(0.319-2.140)

36

Zhong 2014

China

270,66/204

62

192/78

ADC,SCC

I-III

Anti-Ki67; 1:200

50

60

OS,5

R

O:2.179(1.096-4.333)

34

  1. Abbreviation: HR hazard ratio, CI confidence interval, OS overall survival, DFS disease-free survival, NSCLC non-small-cell Lung cancer, ADC adenocarcinoma, SCC squamous carcinoma, R Author reported, O, OS, D,DFS, H High expression, L Low expression, S. curve Survival curve